Rationale: Activation of prosurvival kinases and subsequent nitric oxide (NO) production by certain G protein-coupled receptors (GPCRs) protects myocardium in ischemia/reperfusion injury (I/R) models. GPCR signaling pathways are regulated by GPCR kinases (GRKs), and GRK2 has been shown to be a critical molecule in normal and pathological cardiac function.
M orbidity and mortality of myocardial infarction (MI) remains significant with resulting left ventricular (LV) systolic function presenting as a major determinant of clinical outcome. Protecting the myocardium against ischemia/reperfusion (I/R) injury has become a major target of therapeutic investigation. 1, 2 Included in this approach is limiting myocyte death, which is robustly induced by ischemic/hypoxic conditions. 3 Limiting cell death and infarct size after MI through pharmacological or molecular intervention may significantly reduce LV dysfunction and prevent the development of chronic heart failure (HF). Apoptosis, necrosis, and autophagy have been proposed as mechanisms for the significant amount of cell death occurring in reperfused ischemic myocardium 4 and is thought to contribute significantly to HF progression. 5, 6 Protective signaling pathways involving activation of phosphatidylinositide-3 kinase (PI3K) and its target Akt/protein kinase B mediate cytoprotective effects via phosphorylation of a number of proteins and induction of nitric oxide (NO) production, 1 altogether resulting in limitation of apoptosis and improved myocyte survival. 7, 8 A variety of agents used in clinical management of patients with MI, such as ␤-adrenergic receptor (␤AR) blockers, adenosine, and opioids are thought to impart some cardioprotection via manipulation of G protein-coupled receptor (GPCR) signaling. 3 Importantly, these GPCR ligands have been shown to reduce myocardial apoptotic cell death in animal models of ischemic injury supporting their use as cardioprotective agents. 8 ␤ARs are especially interesting in this regard because ␤ 1 -and ␤ 2 ARs, expressed in myocardium, have differential effects on myocyte survival because ␤ 1 ARs mediate the proapoptotic effects of norepinephrine, 9 whereas ␤ 2 ARs have been shown to promote antiapoptotic signaling via a Gi-mediated mechanism. 10 ␤ARs, and their regulation via GPCR kinases (GRKs) are important therapeutic targets in the management of chronic myocardial disease states such as HF. [11] [12] [13] Of interest to the present study, we have shown that upregulation of GRK2, a biochemical hallmark of failing myocardium, leads to chronic desensitization of ␤ARs and a loss of inotropic reserve.
It has been postulated that increased GRK2 activity in the injured/stressed heart is protective to fight against overstimulation of ␤ARs caused by sympathetic nervous system hyperactivity, however, we have shown that inhibition of GRK2 actually protects the heart against the development of HF. [12] [13] [14] This work has primarily been done using a peptide inhibitor of GRK2, called the ␤ARKct, which is comprised of the carboxyl-terminal 194 amino acids of GRK2 that competes with endogenous GRK2 for membrane binding and activation against GPCR substrates through association with the dissociated G protein ␤␥-subunits (G ␤␥ ). 15 Most recently we have shown that gene transfer of an adeno-associated virus (AAV) containing the ␤ARKct peptide can rescue LV dysfunction chronically in a rat model of HF causing improved cardiac performance and reversal of LV remodeling. 16 Similarly, cardiac-specific knockout of the GRK2 gene after development of LV dysfunction in mice improved cardiac function and morphology. 17 These studies solidify data suggesting that GRK2 is pathological in the heart and its inhibition or lowering of expression is therapeutic.
The present study was designed to determine whether GRK2 upregulation, which has been shown to occur early after ischemic cardiac injury, 18, 19 is beneficial or maladaptive in a model of acute ischemic injury. We have subjected mice with cardiac-specific overexpression of GRK2 or expression of the ␤ARKct to I/R injury and explored specific mechanisms related to myocyte death and survival. Our results clearly show that even in the acute setting, increased GRK2 activity is deleterious to myocytes, and we present novel data demonstrating that inhibition of GRK2 activity specifically toward ␤ 2 ARs can result in cardioprotection.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Experimental Animals
Cardiac-specific transgenic mice with GRK2 overexpression or expression of ␤ARKct have been described previously. 15 All animal procedures were carried out in accordance with the guidelines of the Institutional Animal Care and Use Committee of Thomas Jefferson University.
Model of I/R Injury
I/R was induced by 30 minutes of coronary artery ligation followed by its release and reperfusion as described previously. 20 Infarct size is presented as the infarcted area of left ventricle (LV) within the ischemic area at risk as described previously. 20 The specific ␤ 2 AR antagonist ICI 118,551 (Tocris) and ␤ 2 AR agonist fenoterol (Sigma) were administered in drinking water (0.2 and 250 g/kg per day, respectively) beginning 5 days before and during the I/R protocol. 21
Determination of Myocardial Apoptosis
In vivo myocardial apoptosis was determined using TUNEL staining and caspase-3 activity assay as described previously with minor modifications (see the Online Data Supplement for details). 20, 22 
Neonatal Rat Ventricular Myocyte Isolation and In Vitro Models of I/R Injury or Oxidative Stress
Neonatal rat ventricular myocytes (NRVMs) from 1-to 2-day-old rats were isolated as described previously. 23 Gene delivery of GRK2 or ␤ARKct was carried out in cultured NRVMs using adenoviral vectors. After 48 hours, adenoviral-treated NRVMs were subjected to simulated I/R (medium inducing ischemia-like condition for 45 minutes and reperfusion of 24 hours) as described previously 24 or exposed to oxidative stress (H 2 O 2 , 150 mol/L for up to 16 hours). For some experiments, myocytes were treated with tumor necrosis factor (TNF)␣ (Sigma) or pretreated with inhibitors of PI3K (LY294002, Tocris) or NO synthase (NOS) (N G -nitro-L-arginine methylester [L-NAME]; Sigma).
Measurement of NO Content In Vivo and In Vitro
Total NO content was measured in the LV area at risk using quantification with a chemiluminescence detector (Sievers 280i NO Analyzer) as described previously (see the Online Data Supplement). NO production in cultured myocytes was measured as the stable metabolite nitrite by Griess method according to the protocol of the manufacturer (R&D Systems).
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Western Blot Analysis
Western blotting was performed as described previously. 20 Immunoblots were performed for LV protein levels of phospho Ser473 -Akt, phospho Thr1177 -eNOS (Cell Signaling), GRK2 (Santa Cruz Biotechnology), and GAPDH (Chemicon). All antibodies were used at 1:1000 dilution.
Statistical Analysis
All values are presented as meansϮSEM. Statistical significance of multiple treatments was determined using GraphPad Prism Software Version 5.9 (San Diego, Calif) by Student's t test or ANOVA followed by either Newman-Keuls or Bonferroni post hoc test when appropriate. For all tests, a probability value of Ͻ0.05 was considered significant.
Results
Increased GRK2 Levels and Activity Are Deleterious to Postischemic Myocardium
LV infarct size resulting from temporary coronary artery ligation and 24 hours of reperfusion was measured in transgenic mice with altered cardiac GRK2 expression and activity, and significant differences were found ( Figure 1 ). In control nontransgenic (NLC) mice, LV infarct size was calculated to be 31.3Ϯ2.2% of the area at risk ( Figure 1B ). The NLC group contains combined nontransgenic littermates from GRK2 and ␤ARKct breeding pairs because we found no differences between these control mice (data not shown). In cardiac GRK2-overexpressing transgenic mice, there was enhanced injury as the LV infarct size significantly increased to 43.1Ϯ2.8% (PϽ0.05 compared with NLC and ␤ARKct; Figure 1B ). On the other hand, ␤ARKct expression specifically in myocytes led to cardioprotection as the LV infarct size was significantly reduced to 16.8Ϯ1.3% (PϽ0.05 compared with GRK2 and NLC; Figure 1B ). The area at risk within the LV was similar between all groups ( Figure 1C ). These results demonstrate that GRK2 overexpression is deleterious to the reperfused myocardium in acute I/R injury and that its inhibition via the ␤ARKct can impart a cardioprotective phenotype.
GRK2 Activity in the Postischemic Heart Promotes Apoptosis
Myocardial apoptosis is major factor contributing to I/R injury. 4 Accordingly, we assessed programmed cell death using two independent methods. First, TUNEL staining was used on tissue sections following ischemia and 3 hours of reperfusion and apoptosis assessed in the ischemic border zone surrounding the infarcted area. As shown in Figure 2A , TUNEL-positive nuclei were ubiquitous showing enhanced apoptotic cell death in GRK2-overexpressing myocardium compared with NLC hearts. Interestingly, apoptosis was found to be significantly less in ␤ARKct-expressing post-I/R myocardium. Quantification of these findings are shown in Figure 2B where GRK2 overexpression led to a Ϸ2-fold increase in TUNEL-positive cells compared with post-I/R NLC hearts (437.3Ϯ43.0 nuclei per high-power field versus 257.1Ϯ30.7 nuclei per high-power field; PϽ0.05). In contrast, ␤ARKct expression resulted in Ͼ50% fewer TUNELpositive cells compared with NLC heart after I/R injury (97.3Ϯ10.3 nuclei per high-power field; PϽ0.05 versus NLC and GRK2 mice). Independently, we performed caspase-3 activity measurement in cardiac extracts from the various post-I/R mouse hearts ( Figure 2C ). Similar to the TUNEL results, I/R injury in NLC mice induced significant caspase-3 activity (2.9Ϯ0.4 pmol/mg protein per hour) compared with Sham mice (1.1Ϯ0.2 pmol/mg protein per hour, PϽ0.05) and GRK2 overexpression significantly enhanced this activity (4.5Ϯ0.5 pmol/mg protein per hour; PϽ0.05 versus NLC). As with TUNEL, ␤ARKct expression led to significantly less myocardial caspase-3 activity after I/R (1.3Ϯ0.3 pmol/mg protein per hour; PϽ0.05 versus NLC and GRK2) and actually was not statistically different from sham values ( Figure 2C ). Overall, these results demonstrate a robust effect of the ␤ARKct to limit myocardial apoptosis acutely after ischemic injury.
Cardioprotective Induction of Nitric Oxide Synthesis is Increased by GRK2 Inhibition
One end point of cardioprotective signaling known to be regulated by adrenergic signaling is NOS activity and NO production. Indeed, we found myocardial synthesis of NO increased in the heart after I/R, with ␤ARKct expression significantly augmenting this response (almost doubling), whereas, reciprocally, GRK2 overexpression negated a significant increase in post-I/R NO production in myocardium ( Figure 3A ). This novel result mirrors the findings depicted in Figure 1 and represents a downstream effect of survival signaling resulting in reduced apoptosis and implying that NOS regulation is a major GRK2-dependent pathological mechanisms in the ischemic heart. To further investigate this finding, we used isolated NRVMs with adenoviral-induced overexpression (see the Online Data Supplement) of GRK2, as well as expression of the ␤ARKct peptide, and measured basal and stimulated NO release ( Figure 3B ). GRK2 inhibition via ␤ARKct led to a Ͼ60% higher NO release basally (Ͼ60% versus GRK2 and control), as well as after induction of NO synthesis via TNF␣ together with the catecholamine, norepinephrine by 3-fold, and control (green fluorescent protein [GFP]-infected), and GRK2-overexpressing cells lacked this increase in NO ( Figure 3B) . Importantly, the ␤ARKct-mediated enhancement of NO production was eliminated when cells were pretreated with L-NAME, an inhibitor of NOS, although this inhibitor had no effect in GRK2overexpressing myocytes ( Figure 3B ). Catecholamine stimulation alone did not increase NO production, consistent with previous reports. 25
Cardiomyocyte Apoptosis Following I/R or Oxidative Stress In Vitro Is Reduced by ␤ARKct Expression
To determine whether the differential effects on cell survival found in hearts after I/R could be reproduced in NRVMs, we subjected these cells to simulated I/R conditions or oxidative stress via H 2 O 2 treatment (see the Online Data Supplement).
Using a GFP-adenovirus as a control, NRVMs overexpressed GRK2 to a similar level (3-to 4-fold) seen in GRK2 transgenic mice. 15 Following introduction of these stress conditions, myocytes underwent TUNEL staining ( Figure  4A ). Apoptosis was significantly enhanced by both I/R or H 2 O 2 exposure; however, ␤ARKct expression led to significantly less TUNEL staining compared with GFP-or GRK2overexpressing myocytes ( Figure 4A ). Interestingly, GRK2 overexpression did not result in significantly enhanced apoptosis compared with GFP or ␤ARKct, although there was an upward trend. This difference from the in vivo results was also apparent in NO production ( Figure 3B ), implying either a compensating mechanism only in NRVMs or this could be attributable to the higher density of ␤ 2 ARs potentially causing less desensitization effects in these cells. Alternatively the apoptotic index in NRVMs under our experimental conditions was maximal even without GRK2 overexpression. Importantly, these results do support the robust in vivo data demonstrating the myocyte protective effect after ischemic and oxidative stress induced by the ␤ARKct. Furthermore, disruption of signaling through PI3K, via its inhibitor LY294002, or inhibition of NOS significantly decreased the beneficial effect of ␤ARKct ( Figure 4A ).
Mechanism of ␤ARKct Cardioprotection Involves Akt Activation and Downstream Activation of NOS
Previous studies have shown that prosurvival signaling in ischemic hearts is mediated by Akt phosphorylation downstream of PI3K activation, which can occur following GPCR stimulation. 1-3 Accordingly, we measured Akt phosphorylation as a marker of activation of this kinase in GRK2overexpressing and ␤ARKct overexpressing NRVMs exposed to oxidative stress (150 mol/L H 2 O 2 ). We found a significant increase in Akt phosphorylation after H 2 O 2 treatment in control and ␤ARKct groups, however, GRK2 overexpression significantly blunted Akt phosphorylation to only 44Ϯ9.3% compared with control myocytes (Figure 4B and 4C). Importantly, analysis of Akt phosphorylation in vivo using cardiac extracts from post-I/R GRK2, ␤ARKct and NLC hearts revealed that ␤ARKct expression leads to enhanced Akt activation whereas GRK2 overexpression leads to decreased Akt phosphorylation ( Figure 5A ). Thus, it appears that a loss or gain in activity of GRK2 can have profound reciprocal effects on Akt activation both in vitro and in vivo in myocytes exposed to acute ischemic injury and the altered activity of this prosurvival kinase could explain the above differences in apoptosis. Interestingly, a recent report showed that GRK2 can interact directly with Akt and inhibit its activity, 26 and our present data in myocytes are consistent with this result. One effector known to be downstream of the GRK2-Akt interaction is NOS, 26 and activation of endothelial (e)NOS, as well as inducible NOS, are known to have cytoprotective, as well as antiapoptotic, effects. Parallel to the increase in Akt phosphorylation, we found a significant 47% higher eNOS activation determined by assessing its phosphorylation in post-I/R ␤ARKct hearts compared with NLC ( Figure 5B ). These data are consistent with a prosurvival pathway in myocytes via GRK2 inhibition allowing for increased signaling through the Akt-NOS signaling axis. This is consistent with downstream inhibition of Caspase-3 activity and apo- ptotic cell death. Consistent with this mechanism, the induction of NO production was elevated by catecholamine stimulation in NRVMs expressing ␤ARKct compared with controls, and this effect was abrogated in GRK2-infected cells ( Figure 3B ).
Enhanced GRK2-Mediated I/R Injury and ␤ARKct Cardioprotection Can Be Reversed by Manipulation of ␤ 2 AR Signaling
GPCR targets of myocardial GRK2 activity are the ␤ARs. 12,13 ␤ 1 -and ␤ 2 AR subtypes have opposing actions on myocyte apoptosis with ␤ 2 ARs, promoting cell survival. 9, 10 To investigate whether ␤ARKct-mediated cardioprotection may involve enhanced signaling through ␤ 2 ARs (via a lack of desensitization), we treated ␤ARKct mice with the selective ␤ 2 AR antagonist ICI 118,551 and subjected them to I/R injury. As shown in Figure 6A and 6B, ␤ARKct mice treated with ICI 118,551 no longer had reduced infarct sizes and myocardial injury was the same as in NLC mice. As in the above data ( Figure 1 ) the area at risk after I/R was the same in both groups ( Figure 6C ). In a similar fashion, we treated NLC and GRK2-overexpressing transgenic mice with the Figure 6 . Post-I/R injury in ␤ARKct and GRK2 transgenic mice are reversed by ␤ 2 AR modulation. A, Representative photographs of TTC-stained sections from post-I/R NLC and ␤ARKct mice treated with the ␤ 2 AR-selective antagonist ICI 118,551. B, LV infarct size (IS) expressed as percentage of the area at risk (AR) in NLC and ␤ARKct groups shows no significant difference (nϭ11 to 13/group; PϭNS). C, AR expressed as percentage of the total LV in NLC and ␤ARKct mice is comparable. D, Representative photographs of TTC-stained sections from post-I/R NLC and cardiac GRK2-overexpressing mice treated with the ␤ 2 AR agonist fenoterol. E, IS/AR ratio is the same in NLC and GRK2 groups (nϭ6 to 10, PϭNS). F, AR/LV did not show any difference between NLC and GRK2 mice. This study shows that cardioprotective signaling through GPCRs such as the ␤ 2 AR can negatively be affected by GRK2 expression and activity through inhibition of Akt. Moreover, GRK2 inhibition by the ␤ARKct expression eliminates this negative Akt influence, increasing downstream prosurvival signaling that includes decreased caspase-3 activity, as well as enhanced activation of eNOS and NO production, which reduces apoptosis and cell death. selective ␤ 2 AR agonist fenoterol before subjecting them to I/R injury. Interestingly, when treated with fenoterol, LV infarct size in GRK2 mice was no longer increased compared with NLC injury (Figure 6D through 6F) . These results suggest that the ␤ 2 AR signaling is playing a significant role in how GRK2 influences post-I/R injury because, importantly, antagonizing ␤ 2 AR signaling reversed the prosurvival events mediated by GRK2 inhibition.
Discussion
In this study, we have found that GRK2 is a key pathological regulator of the myocardial response to acute ischemic injury. Using transgenic mice with a gain or loss of function of this enzyme in cardiac myocytes we have found a profound reciprocal effect on I/R induced myocardial injury and resultant apoptotic response. Importantly, our findings include that in the setting of I/R, inhibition of GRK2 can impart cardioprotection with significant myocardial salvage through survival signaling resulting from increased NO production downstream of Akt activation.
These novel findings using the ␤ARKct add acute ischemic cardioprotection to the beneficial effects of GRK2 inhibition already shown in chronic HF models. Studies using viralmediated gene delivery of the ␤ARKct to myocardium has led to prevention and even reversal of HF, 16, 19, 27 including a study demonstrating reversal of contractile dysfunction in failing human ventricular myocytes. 28 Most recently, we have shown that ␤ARKct delivery to a failing rat heart using AAV6-based gene therapy can chronically alter the disease, leading to improved cardiac function and reversal of pathological LV remodeling. 16 Interestingly, especially in light of our present results, ␤ARKct gene delivery to rabbit hearts has led to acute functional improvement globally in hearts undergoing ischemic insult either by cardioplegic arrest 29 or permanent coronary artery ligation and MI. 30 Of note, our present study adds important mechanistic insight into how ␤ARKct expression not only can improve contractile function of ischemic myocytes but also leads to prosurvival signaling to prevent I/R-induced cell death, leading to an increased amount of viable myocardium. It appears that ␤ARKct expression leads to increased activation of the prosurvival kinase Akt and downstream effectors, such as NO, after acute I/R injury. Moreover, this cell survival signaling pathway may be induced by the ␤ 2 AR, which would be less desensitized with GRK2 inhibition.
Data with the ␤ARKct are significant from a therapeutic point of view, but our results with clinically significant myocardial GRK2 overexpression (3-to 4-fold), which is the same found in failing human myocardium, 31 are critical in proving GRK2 as a pathological target in the heart. GRK2 is increased to this level in several animal models of cardiac injury 18, 32, 33 and appears to be among the first molecular changes after myocardial ischemia. 19, 34 Interestingly, we found in this study that elevated myocyte GRK2 activity leads to increased cell death after I/R injury through an increased apoptotic index. Moreover, our data are consistent with a lack of Akt activation, which GRK2 has recently been shown to interact with and inhibit. 26 A previous study focusing solely on cardiac contractile function and ␤AR responsiveness also found that this level of GRK2 overexpression leads to an intolerance to ex vivo ischemia. 35 Moreover, in a recent study using cardiac-specific GRK2 gene deletion, we have found that induced loss of GRK2 two weeks after a MI significantly prevents all subsequent death. 17 Thus, our data clearly show enhanced GRK2 to be pathological in acutely injured myocardium, resulting, in part, from an inhibition of Akt activity.
Interestingly, Ad-GRK2-infected cultured neonatal cardiomyocytes did not show significantly enhanced apoptotic indices after oxidative stress probably because of compensating mechanisms, for instance, the higher expression of protective ␤ 2 AR in neonatal myocytes, as well as less sensitivity to catecholamines, compared with adult cardiac myocytes. 36 Nonetheless, ␤ARKct expression clearly prevents ischemic apoptosis of myocytes and it appears that this novel cardioprotective effect of ␤ARKct is mediated via enhanced Akt activation. In light of the findings that GRK2 can interact with and inhibit Akt, it might be rather intuitive to find increased Akt with ␤ARKct expression, however, this has not been previously documented and our results demonstrate this finding for the first time in the heart. The Akt/eNOS signaling axis, which has been shown to play a critical role in postinjury production of NO and protection from cell death, 37 also appears to be a direct effector of ␤ARKct-mediated cardioprotection. Because the cardioprotective role of NO in I/R injury is clearly established, 38 as well as a novel role for its metabolite nitrite, 39 our data permit the conclusion that indeed, the antiapoptotic effect of GRK2 inhibition involves this important downstream effector.
Another novel aspect of our study is the finding that the reciprocal effects of GRK2 and ␤ARKct in cardiac injury after I/R could be reversed in a ␤ 2 AR-dependent manner with a ␤ 2 AR agonist protecting against GRK2-induced injury and a ␤ 2 AR antagonist negating the cardioprotective effects of ␤ARKct. These results could point toward differential regulation of ␤AR subtypes by GRK2, or even if the affinity for GRK2-mediated desensitization of the two receptors is equal (which is believed to be the case), ␤ 2 ARs could be more tightly coupled to cell survival signaling pathways. Clearly, ␤ 1 ARs and ␤ 2 ARs are coupled to different intracellular pathways leading to either Gs stimulation in the case of the ␤ 1 AR or dual coupling to Gs and Gi for the ␤ 2 AR. 12, 40 Downstream of the ␤ 1 AR, protein kinase A activation 9, 40, 41 and Ca 2ϩ /calmodulin-dependent kinase II activation 42, 43 are known stimulators of myocyte apoptosis. On the other hand, ␤ 2 AR coupling to Gi leads to cell survival and reduced apoptosis. 10, 44 As shown in our present study, the ␤ARKctmediated protective phenotype can be reversed by blocking ␤ 2 AR with the addition of ICI 118,551, implying a ␤ 2 AR-Gi-dependent mechanism in play following I/R that is enhanced when GRK2 is inhibited. Similarly, stimulating ␤ 2 AR with the selective agonist fenoterol prevented the enhanced post-I/R injury with GRK2 overexpression. These results further promote the idea that ␤ 2 AR signaling (via Akt/eNOS) is cardioprotective in acute myocardial injury and demonstrates that GRK2 is a key regulator of this pathway in the heart (see Figure 7) .
In contrast to our findings, a previous study using an ex vivo perfusion system found that ischemic preconditioninginduced cardioprotection (IPC) was not enhanced by the expression of ␤ARKct. 11 Importantly, significant differences between this model and our present study (ex vivo versus in vivo) and protocols (global ischemia versus single-vessel occlusion) may explain this discrepancy. However, consistent with our results was the finding that inhibition of Gi signaling with pertussis toxin could blunt IPC-induced protection ex vivo, 11 and hearts lacking the ␤ 2 AR had a blunted response to IPC. 45 These data are in agreement with our observations where the ␤ 2 AR-Gi signaling is protective and desensitization evoked by GRK2 activity leads to deleterious outcome in I/R.
Mechanistically, a caveat that cannot be ignored is that the effects of ␤ARKct expression in the I/R injury model may be attributable to the sequestration of G ␤␥ independent of GRK2 activation. Certainly, G ␤␥ inhibition is a potential effect of the ␤ARKct. However, our data with enhanced Akt activation and reversal of ␤ARKct-mediated cardioprotection by ␤ 2 AR blockade argue that inhibition of GRK2 activity appears to play a major mechanistic role in our present results. Therefore, overall, our results represent a novel extension to the beneficial effects of GRK2 inhibition in myocardium showing that beyond prevention of chronic HF, ␤ARKct expression can impart novel ␤ 2 AR-mediated cardioprotection.
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